AbbVie Inc. (ABBV)
AbbVie: Growth-Pharma Profile At A Value-Pharma Price
AbbVie Inc. is rated a 'Buy' on accelerating fundamentals, robust pipeline progress, and a macro backdrop favoring defensive growth. SKYRIZI and RINVOQ are projected to deliver ~$31.8 billion in FY2026E revenue, with neuroscience emerging as a second growth pillar targeting ~$12.6 billion. EPS is expected to surge ~43% to $14.26 in FY2026E, with FCF up 54% and net debt/EBITDA declining to 1.6x.
Up 45% Since 2024: 1 Glaring Reality That Makes AbbVie Stock a Hold at $225
AbbVie (NYSE:ABBV | ABBV Price Prediction) at $224.95 sits at the center of a sharp bull-bear debate.
Will Skyrizi & Rinvoq Continue to Drive AbbVie's Topline Through 2026?
ABBV's Skyrizi and Rinvoq post strong Q1 growth, lift 2026 sales outlooks and sustain momentum through new indications.
Healthcare ETFs: From Broad Exposure to Big Breakthroughs
With AI and space dominating many of the market's most popular investment themes, it can be difficult to find differentiated opportunities. Healthcare is often viewed as one of the more defensive sectors, supported by relatively steady demand regardless of the economic environment.
3 Dividend Stocks Built for Retirement to Buy in June
Mid-year is when income-focused investors tend to take a hard look at their portfolios.
AbbVie Inc. (ABBV) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
AbbVie Inc. (ABBV) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Middle East Erupts Again: Buy these Healthcare ETFs Before the Next Strike
Healthcare ETFs are gaining attention as Middle East tensions and market volatility boost demand for defensive sectors.
Should You Buy, Sell or Hold ABBV Stock After It Rises 12% in a Month?
ABBV climbs 12% a month as investors weigh the raised 2026 guidance, Skyrizi and Rinvoq growth, and multiple pipeline updates.
AbbVie (ABBV) Ascends While Market Falls: Some Facts to Note
AbbVie (ABBV) closed at $227.23 in the latest trading session, marking a +1.02% move from the prior day.
Does Decnupaz Approval Validate ABBV's ADC Strategy in Oncology?
AbbVie's FDA approval of Decnupaz for BPDCN marks its first blood cancer ADC and expands a strategy built on deals and internal development.
AbbVie Delivers 400% Returns Beating The S&P 500 by 139%
Ten years ago, AbbVie (NYSE:ABBV | ABBV Price Prediction) was a one-drug story.
AbbVie Gets EU Nod for Aquipta as Acute Treatment for Migraine
ABBV wins EU approval for Aquipta for acute migraine treatment in adults, adding a second approved indication in migraine.
